top of page

Mwandishi

Mhariri:

ULY CLINIC

Dkt. Peter A, MD

16 Juni 2021, 19:09:27

Amoxiclavu na ujauzito

Amoxiclavu na ujauzito

Tafiti nyingi zimeelezea matumizi ya amoxicillin na potassium clavulanate ( kwa jina jingine amoxiclavu au amoxicillin–clavulanic) kutibu maambukizi mbalimbali kwa mama mjamzito. Tafiti nyingi zimeonyesha kutokuwepo kwa madhara kwa kijusi na mtoto anayezaliwa. Hata hivyo tafiti moja imeripoti kuwa kuna mahusiano kati ya matumizi ya dawa hii na kutokea kwa ugonjwa wa kuoza kwa utumbo wa mtoto kwa vichanga wanaozaliwa.


Ushauri dhidi ya matumizi kwa mama mjamzito


Inapatana na ujauzito


Inapatana na ujauzito ina maanisha nini?

Uzoefu wa matumizi kwa binadamu kuhusu dawa hii au dawa zingine zilizo kundi moja au zenye kufanya kazi kwa utaratibu unaofanana, zinatosha kuonyesha kuwa, madhara kwa kichanga tumboni ni madogo sana au hakuna kabisa. Tafiti za uzazi kwa wanyama hazina uhalisia kwa binadamu.


Ushauri wa matumizi kwa mama anayenyonyesha


Hakuna (chache) taarifa za binadamu- Inawezekana patana na unyonyeshaji


Hakuna (chache) taarifa za binadamu- Inawezekana patana na unyonyeshaji ina maanisha nini?

Hakuna taarifa za uzoefu kuhusu matumizi ya dawa hii kwa mama anayenyonyesha au kuna taarifa chache. Taarifa chache zilizopo zinaonyesha kuwa dawa hii haiwasilishi hatari yenye mashiko kwa kichanga anayenyonya maziwa ya mama anayetumia dawa.

ONYO: Usitumie dawa yoyote bila ushauri wa daktari. Dawa zinaweza kuleta madhara mwilini na pia matumizi ya baadhi ya dawa pasipo ushauri na vipimo husababisha  vimelea kuwa sugu dhidi ya dawa hiyo.
ULY clinic inakushauri kuwasiliana na daktari wako unapotaka kuchukua maamuzi yoyote yanayohusu afya yako.
Wasiliana na daktari/Mfamasia wa ULY clinic kwa ushauri na Tiba au kuandikiwa dawa kwa kupiga simu au Kubonyeza Pata tiba chini ya tovuti hii.

Imeboreshwa,

4 Juni 2025, 18:49:18

​

  1. Baldwin JA, et al. Reproduction studies of BRL14151K and BRL25000. I. Teratology studies in rats. Chemotherapy (Tokyo). 1983;31(Suppl 2):238–51.

  2. Baldwin JA, et al. Reproduction studies of BRL14151K and BRL25000. II. Peri- and post-natal studies in rats. Chemotherapy (Tokyo). 1983;31(Suppl 2):252–62.

  3. Hirakawa T, et al. Reproduction studies of BRL14151K and BRL25000. III. Fertility studies in rats. Chemotherapy (Tokyo). 1983;31(Suppl 2):263–72.

  4. James PA, et al. Reproduction studies of BRL25000. IV. Teratology in pig. Chemotherapy (Tokyo). 1983;31(Suppl 2):274–9.

  5. Tasker TCG, et al. Safety of ticarcillin/potassium clavulanate. J Antimicrob Chemother. 1986;17:225–32.

  6. Matsuda S, et al. Fundamental and clinical studies on BRL25000 (clavulanic acid–amoxicillin) in the field of obstetrics and gynecology. Chemotherapy (Tokyo). 1982;30(Suppl 2):538–47.

  7. Takase Z, et al. Clinical and laboratory studies on BRL25000 (clavulanic acid–amoxicillin) in the field of obstetrics and gynecology. Chemotherapy (Tokyo). 1982;30(Suppl 2):579–86.

  8. Fortunato SJ, et al. Transfer of Timentin (ticarcillin and clavulanic acid) across the in vitro perfused human placenta: comparison with other agents. Am J Obstet Gynecol. 1992;167:1595–9.

  9. Matsuda S. Augmentin treatment in obstetrics and gynaecology. In: Leigh DA, Robinson OPW, editors. Augmentin: Proceedings of an International Symposium, Montreux, Switzerland, July 1981. Excerpta Medica. 1982;179–91.

  10. Mayer HO, et al. Augmentin in the treatment of urinary tract infection in pregnant women and pelvic inflammatory disease. In: Proceedings of the European Symposium on Augmentin, Scheveningen, June 1982. 1983;207–17.

bottom of page